References
- Berndt, Ernst R., and Joseph P. Newhouse. 2010. Pricing and Reimbursement in U.S. Pharmaceutical Markets. National Bureau of Economic Research, Working Paper No. 16297.
- Berndt, Ernst R., Richard Mortimer, Ashoke Bhattacharjya, Andrew Parece, and Edward Tuttle. 2007. Authorized Generic Drugs, Price Competition, and Consumers’ Welfare. Health Affairs (Project Hope) 26 (3): 790–799. doi:https://doi.org/10.1377/hlthaff.26.3.790.
- Caves, Richard E., Michael D. Whinston, and Mark A. Hurwitz. 1991. Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry. Brookings Papers on Economic Activity: Microeconomics 22: 1–66.
- Chen, Tom. 2007. Authorized Generics: A Prescription for Hatch-Waxman Reform. Virginia Law Review 93 (2): 459–513.
- Conti, Rena M., and Ernst R. Berndt. 2018. Specialty Drug Prices and Utilization after Loss of US Patent Exclusivity, 2001-2007. In Measuring and Modeling Health Care Costs, Vol. 76. NBER Studies in Income and Wealth.
- Frank, Richard G., and David S. Salkever. 1997. Generic Entry and the Pricing of Pharmaceuticals. Journal of Economics & Management Strategy 6 (1): 75–90. doi:https://doi.org/10.1162/105864097567039.
- FTC. 2011. Authorized Generic Drugs: Short-Term Effects and Long-Term Impact. A Report of the Federal Trade Commission.
- Grabowski, Henry G., and John M. Vernon. 1996. Longer Patents for Increased Generic Competition in the US: The Waxman-Hatch Act after One Decade. Pharmacoeconomics 10 (Supplement 2): 110–123. doi:https://doi.org/10.2165/00019053-199600102-00017.
- Kamien, Morton I., and Israel Zang. 1999. Virtual Patent Extension by Cannibalization. Southern Economic Journal 66 (1): 117–131. doi:https://doi.org/10.2307/1060838.
- Lakdawalla, Darius N., Tomas J. Philipson, and Y. Richard Wang. 2006. Intellectual Property and Marketing. National Bureau of Economic Research, Working Paper 12577.
- Regan, Tracy. 2008. Generic Entry, Price Competition, and Market Segmentation in the Prescription Drug Market. International Journal of Industrial Organization 26 (4): 930–948. doi:https://doi.org/10.1016/j.ijindorg.2007.08.004.
- Saha, Atanu, and Heather Roberts. 2020. Pharmaceutical Industry’s Changing Market Dynamics. International Journal of the Economics of Business 27 (2): 159–175. doi:https://doi.org/10.1080/13571516.2020.1752044.
- Saha, Atanu, Henry Grabowski, Howard Birnbaum, Paul Greenberg, and Oded Bizan. 2006. Generic Competition in the US Pharmaceutical Industry. International Journal of the Economics of Business 13 (1): 15–38. doi:https://doi.org/10.1080/13571510500519905.
- Scherer, Frederic M. 1993. Pricing, Profits, and Technological Progress in the Pharmaceutical Industry. Journal of Economic Perspectives 7 (3): 97–115. doi:https://doi.org/10.1257/jep.7.3.97.
- Suh, D. C., W. G. Manning, Stephen W. Schondelmeyer, and R. S. Hadsall. 2000. Effect of Multiple-Source Entry on Price Competition after Patent Expiration in the Pharmaceutical Industry. Health Services Research 35 (2): 529–547.
- Wiggins, Steven N., and Robert Maness. 2004. Price Competition in Pharmaceuticals: The Case of anti-Infectives. Economic Inquiry 42 (2): 247–263. doi:https://doi.org/10.1093/ei/cbh058.